What Bio-Techne's latest 10-K says: 11 signals
Bio-Techne filed its latest 10-K with the SEC on Aug 24, 2026. It discusses acquisition announced, acquisition completed and capex increase.
Public (TECH)Biotechnology Research1,001 to 5,000 employeesbio-techne.comLinkedIn
- Filed
- Aug 24, 2026
- Filings
- 1
- Signals
- 11
10-K · latest 10
What Bio-Techne's 10-K filings say
- SEC EDGAR
10-K
Filed · 11 signals
Bio-Techne completed acquisition of spatial biology firm Lunaphore in fiscal 2024
spatial biologyproteomicstranscriptomicsmicrofluidic technology
Bio-Techne names major competitor Thermo Fisher Scientific as a key distribution partner
The company relies on Thermo Fisher Scientific, a direct competitor in the life sciences space, for product distribution.
Thermo Fisher Scientific
Executing M&A strategy with Lunaphore acquisition and future purchase of Wilson Wolf by 2027
The company is actively using acquisitions for growth, having recently bought Lunaphore and committed to acquiring the remainder of Wilson Wolf.
Thermo Fisher Scientific
Facing stricter EU In Vitro Diagnostic Regulation (IVDR), requiring system and process changes
New EU IVDR rules are imposing significant compliance costs, potentially requiring material modifications to quality management systems, additional resources, and updates to technical files.
Integrating Lunaphore acquisition and planning full takeover of Wilson Wolf by 2027.
19.9%
initial investment in Wilson Wolf Corporation
cell and gene therapyThermo Fisher Scientific
Bio-Techne to acquire remaining 80.1% of Wilson Wolf by end of 2027
The company has a definitive plan to fully acquire Wilson Wolf, a key partner in the high-growth cell and gene therapy market.
80.1%
remaining ownership of Wilson Wolf to be acquired
cell and gene therapycell cultureWilson Wolf Corporation
Bio-Techne is executing a strategic expansion into diagnostics and therapeutics markets
A core strategic pillar is to penetrate the regulated diagnostics and therapeutics markets, moving beyond its traditional research focus.
diagnosticstherapeutics
Running executive-sponsored 'Belonging' initiative with 11 global Employee Resource Groups
The company is actively investing in DEI through an executive-sponsored initiative focused on education, broadening candidate pools, and sustaining programs like its 11 ERGs.
44%
of managerial employees are female
Facing stricter EU IVDR and data privacy (GDPR, CCPA) compliance requirements.
New regulations like the EU's In Vitro Diagnostic Regulation (IVDR) are forcing "material modifications" to quality management systems and processes.
Thermo Fisher Scientific
Bio-Techne is actively expanding its global sales staff and distribution channels
The company is committed to growing its global presence to improve customer access and increase market share, particularly in North America, Europe, and Asia.
Showing 10 of 11 filing signals. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Bio-Techne with the Signal API
One POST /v1/companies/enrich call with bio-techne.com returns Bio-Techne 10-K signals (sec-10k), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"bio-techne.com","signal_types":["sec-10k"],"limit":20}'Same industry
10-K at related companies
Questions about Bio-Techne 10-K
When did Bio-Techne file its latest 10-K?
What does Bio-Techne's latest 10-K say about acquisition completed?
Where can I find Bio-Techne's annual report?
Source. Annual reports (Form 10-K) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .